Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...
European shares ended higher on Monday in broad-based gains led by banks, kicking off a week packed with central bank ...
Scribe Therapeutics Inc. (Scribe), a genetic medicines company pioneering next-generation in vivo CRISPR-based medicines designed to be safe, durable, and effective enough to become standard-of-care ...
Italian non-profit rare and complex genetic diseases specialist Fondazione Telethon (FT) and Orphan Therapeutics Accelerator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback